Investigational drug · Phase 2
EB-DNK102 dual-targeting CAR-NK cells
Also called: CLDN18.2 + MUC1
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease, Unresectable Locally Advanced.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "EB-DNK102 dual-targeting CAR-NK cells"
First trial start
2026
Feb 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EB-DNK102 dual-targeting CAR-NK cells", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Unresectable Locally Advanced or Metastatic Disease
- Unresectable Locally Advanced
- Metastatic Disease
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "EB-DNK102 dual-targeting CAR-NK cells" as an intervention, largest first.
Beijing BiotechIndustry
NCT07627711 · 42 participants (planned) · Start Mar 2, 2026 · Primary completion Apr 14, 2027
Drug: EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1); EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1) and 1 more · For: Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced; Metastatic Disease
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07480928 · 42 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1); EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1) and 1 more · For: Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease
Sites: Shenzhen, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pancreatic Ductal Adenocarcinoma (PDAC)
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- zoldonrasibPhase 34 trials
Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC
- [18F]FAPI-74 PETPhase 33 trials
SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- Precemtabart tocentecanPrecem-TcT, M9140Phase 32 trials
EMD Serono Research & Development Institute, Inc. · Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.